A Prospective, Single Dose, Randomized, Open-label, Crossover, Comparative Study to Establish Bioequivalence in Healthy Subjects Between the Puran T4® (Sanofi Aventis Farmacêutica Ltda) vs. the New Formulation of Levothyroxine (Eutirox NF® Merck) Administered Orally as 3 Tablets of 200 μg
Latest Information Update: 28 Mar 2024
At a glance
- Drugs Levothyroxine sodium (Primary)
- Indications Hypothyroidism
- Focus Pharmacokinetics
- Sponsors Merck KGaA
Most Recent Events
- 28 Mar 2024 New trial record